合作类型：技术     行业类别: 医药研发    过期时间：2016年04月03日    

瑞士大学已经合成了一个家庭的双核的芳烃钌(II)配合物(小分子)与高细胞毒性的癌细胞。目前正在寻求工业合作伙以及能进一步研发先导化合物的合作伙伴。

英文原文：A Swiss university has synthesized a family of dinuclear arene ruthenium(II) complexes (small molecules) with high cytotoxicity for cancer cells. Compared to platinum-based, ruthenium-based anti-cancer therapies have shown fewer side effects and similar or higher anti-cancer activity. The university is now seeking an industrial partner to further develop lead compounds. Licensing agreement is sought. Family of dinuclear ruthenium complexes displaying high cytotoxicity in cancer cells - Well-balanced lipophilicity (arene ligands) and hydrophilicity (ionic nature) - Good solubility (chloride salts) and good uptake by cancer cells - Expandable family of compounds - Ruthenium displays 2 more ligand-binding possibilities compared to platinum, allowing for coupling of additional entities to interfere with a variety of biological targets.